Foghorn Therapeutics (FHTX) Shares Outstanding (Diluted Average) (2020 - 2026)
Foghorn Therapeutics (FHTX) recorded quarterly Shares Outstanding (Diluted Average) of $69.5 million in Q1 2026, up 10.41% quarter-over-quarter from $63.0 million in Q4 2025, and up 10.65% on a YoY basis from $62.8 million in Q1 2025.
Foghorn Therapeutics (FHTX) Shares Outstanding (Diluted Average) (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' Shares Outstanding (Diluted Average) history runs 7 years deep, the most recent figure standing at $69.5 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 10.65% year-over-year to $69.5 million; the TTM figure through Mar 2026 stood at $69.5 million (up 10.65% YoY), while the FY2025 annual figure was $63.0 million, up 14.72% from the prior year.
- Shares Outstanding (Diluted Average) was $69.5 million for Q1 2026 at Foghorn Therapeutics, up from $63.0 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $69.5 million in Q1 2026 to a low of $41.4 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $51.0 million across 5 years, with a median of $42.4 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Diluted Average) soared 48.96% in 2024, then grew 0.68% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $41.6 million in 2022, then gained by 0.92% to $42.0 million in 2023, then surged by 30.79% to $54.9 million in 2024, then increased by 14.72% to $63.0 million in 2025, then advanced by 10.41% to $69.5 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $69.5 million (Q1 2026), $63.0 million (Q4 2025), and $63.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - | 69.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.54 Mn |
| Dec 31, 2025 | 62.98 Mn |
| Sep 30, 2025 | 63.03 Mn |
| Jun 30, 2025 | 62.91 Mn |
| Mar 31, 2025 | 62.85 Mn |
| Dec 31, 2024 | 54.90 Mn |
| Sep 30, 2024 | 62.60 Mn |
| Jun 30, 2024 | 51.58 Mn |
| Mar 31, 2024 | 42.43 Mn |
| Dec 31, 2023 | 41.97 Mn |
| Sep 30, 2023 | 42.03 Mn |
| Jun 30, 2023 | 41.82 Mn |
| Mar 31, 2023 | 41.81 Mn |
| Dec 31, 2022 | 41.59 Mn |
| Sep 30, 2022 | 41.67 Mn |
| Jun 30, 2022 | 41.52 Mn |
| Mar 31, 2022 | 41.37 Mn |
| Dec 31, 2021 | 37.17 Mn |
| Sep 30, 2021 | 36.88 Mn |
| Jun 30, 2021 | 36.83 Mn |